News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study



6/2/2014 9:54:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASEL, Switzerland, June 2, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that phase 1 study results of its investigational oncology drug, BAL101553, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, U.S.A. The maximum tolerated dose (MTD) was determined and the results indicated first evidence of clinical antitumor activity.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES